Potent and orally active non-peptide antagonists of the human melanocortin-4 receptor based on a series of trans-2-disubstituted cyclohexylpiperazines

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 19, 2005, Pages 4389-4395

  Tucci, Fabio C ^a   White, Nicole S ^a   Markison, Stacy ^a   Joppa, Margaret ^a   Tran, Joe A ^a   Fleck, Beth A ^a   Madan, Ajay ^a   Dyck, Brian P ^a   Parker, Jessica ^a   Pontillo, Joseph ^a   Arellano, L Melissa ^a   Marinkovic, Dragan ^a   Jiang, Wanlong ^a   Chen, Caroline W ^a   Gogas, Kathleen R ^a   Goodfellow, Val S ^a   Saunders, John ^a   Foster, Alan C ^a   Chen, Chen ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

Antagonists; Food intake; GPCR; Melanocortin 4 receptor; SAR

Indexed keywords

HORMONE RECEPTOR BLOCKING AGENT; MELANOCORTIN 4 RECEPTOR; PEPTIDE; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; EMBRYO; FOOD INTAKE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; RAT; RECEPTOR AFFINITY; STATISTICAL SIGNIFICANCE; SUBSTITUTION REACTION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CACHEXIA; EATING; HUMANS; PIPERAZINES; PROTEIN BINDING; RATS; RECEPTOR, MELANOCORTIN, TYPE 4; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 23944510215     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.06.071     Document Type: Article

References (25)

1. A. Inui CA Cancer J. Clin. 52 2002 72
2. M. Larkin Lancet 351 1998 1336
3. J.M. Argiles, S.H. Meijsing, J. Pallares-Trujillo, X. Guirao, and F.J. Lopez-Soriano Med. Res. Rev. 21 2001 83
4. A.P. López, M.R. Figuls, G.U. Cuchi, E.G. Berenstein, B.A. Pasies, M.B. Alegre, and M. Herdman J. Pain Symptom Manage. 27 2004 360
5. J.E.S. Wikberg, R. Muceniece, I. Mandrika, P. Prusis, C. Post, and A. Skottner Pharmacol. Res. 42 2000 393
6. V. Goodfellow, and J. Saunders Curr. Topic Med. Chem. 3 2003 855
7. J. Ballesteros, L. Shi, and J.A. Javitch Mol. Pharmacol. 60 2001 1
8. D.L. MacNeil, A.D. Howard, X. Guan, T.M. Fong, R.P. Nargund, M.A. Bednarek, M.T. Goulet, D.H. Weinberg, A.M. Strack, D.J. Marsh, H.Y. Chen, C.-P. Shen, A.S. Chen, C.I. Rosenblum, T. MacNeil, M. Tota, E.D. MacIntyre, and L.H.T. Van der Ploeg Eur. J. Pharmacol. 450 2002 93
9. A.C. Foster, M. Joppa, S. Markinson, K. Gogas, B.A. Fleck, B. Murphy, M. Wolff, M.J. Cismowski, N. Ling, V.S. Goodfellow, C. Chen, J. Saunders, and P.J. Conlon Ann. N. Y. Acad. Sci. 994 2003 103 and references cited therein
10. D.L. Marks, N. Ling, and R. Cone Cancer Res. 61 2001 1432
11. B.E. Wisse, R.S. Frayo, M.W. Schwartz, and D.E. Cummings Endocrinology 142 2001 3292
12. T.J. Vos, A. Caracoti, J. Che, M. Dai, C.A. Farrer, N.E. Forsyth, S.V. Drabic, R.A. Horlick, D. Lamppu, D.L. Yowe, S. Balani, P. Li, H. Zeng, I.B.J.K. Joseph, L.E. Rodriguez, and C.F. Claiborne J. Med. Chem. 47 2004 1602
13. D.L. Marks, A.A. Butler, and R.D. Cone Ann. Edocrinol. (Paris) 63 2002 121
14. P.A. Arasasingham, C. Fotsch, X. Ouyang, M.H. Norman, M.G. Kelly, K.L. Stark, B. Karbon, C. Hale, J.W. Baumgartner, M. Zambrano, J. Cheetham, and N.A. Tamayo J. Med. Chem. 46 2003 9
15. S. Chaki, S. Hirota, T. Funakoshi, Y. Suzuki, S. Suetake, T. Okubo, T. Ishii, A. Nakazato, and S. Okuyama J. Pharmacol. Exp. Ther. 304 2003 818
16. T.H. Marsilje, J.B. Roses, E.F. Calderwood, S.G. Stroud, N.E. Forsyth, C. Blackburn, D.L. Yowe, W. Miao, S.V. Drabic, M.D. Bohane, J.S. Daniels, P. Li, L. Wu, M.A. Patane, and C.F. Claiborne Bioorg. Med. Chem. Lett. 14 2004 3721
17. J. Pontillo, J.A. Tran, B.A. Fleck, D. Marinkovic, M. Arellano, F.C. Tucci, M. Lanier, J. Nelson, J. Parker, J. Saunders, B. Murphy, A.C. Foster, and C. Chen Bioorg. Med. Chem. Lett. 14 2004 5605
18. J. Pontillo, J.A. Tran, M. Arellano, B.A. Fleck, R. Huntley, D. Marinkovic, M. Lanier, J. Nelson, J. Parker, J. Saunders, F.C. Tucci, W. Jiang, C.W. Chen, N.S. White, A.C. Foster, and C. Chen Bioorg. Med. Chem. Lett. 14 2004 4417
19. C. Chen, J. Pontillo, B.A. Fleck, Y. Gao, J. Wen, J.A. Tran, F.C. Tucci, A.C. Foster, and J. Saunders J. Med. Chem. 49 2004 6821
20. For the rationale behind the design of these MC4R antagonists, including the role of the d-2,4-dichlorophenylalanine, please see Ref. 19.
21. C. Cimarelli, and G. Palmieri J. Org. Chem. 61 1996 5557
22. See supporting information for X-Ray data on compound 9. Crystallographic data (excluding structure factors) for the structures in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication numbers CCDC 270115. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44 (0)1223 336033 or e-mail: deposit@ccdc.cam.ac.uk].
23. S.A. Nickolls, M.I. Cismowski, X. Wang, M. Wolff, P.J. Conlon, and R.A. Maki J. Pharmacol. Exp. Ther 304 2003 1217
24. a's = 8.9 and 6.6. Calculations were performed with ACD/Labs 8.00. Advanced Chemistry Development Inc.
25. S. Markison, A.C. Foster, C. Chen, G.B. Brookhart, A. Hesse, S.R.J. Hoare, B.A. Fleck, B.T. Brown, and D.L. Marks Endocrinology 146 2005 2766